What were the main drivers of Merck's net income increase in Q3 2015 compared to Q3 2014?

The significant increase in net income in Q3 2015 was primarily driven by a reduction in costs and expenses. This included lower materials and production costs, marketing and administrative expenses, and research and development costs, as well as gains from acquisitions and divestitures. Notably, restructuring costs decreased significantly year-over-year.

How did the acquisitions and divestitures impact Merck's sales in Q3 2015?

The acquisition of Cubist Pharmaceuticals contributed positively to sales, adding $362 million in the third quarter. However, the divestiture of the Consumer Care business and certain ophthalmic products negatively impacted overall sales by approximately $480 million in the third quarter. The termination of the AstraZeneca LP relationship also reduced sales.

What is the outlook for Keytruda, and how is it performing?

Keytruda is performing very strongly, with sales of $159 million in Q3 2015 and $352 million for the first nine months of 2015. The drug received accelerated approval for melanoma and non-small-cell lung cancer and is undergoing further regulatory reviews and clinical trials across a broad range of cancer types, indicating significant growth potential.

What significant legal or litigation matters is Merck currently involved in?

Merck is involved in several significant legal proceedings, including ongoing product liability lawsuits related to Vioxx and Fosamax, as well as securities litigation. The company is also defending against patent infringement claims related to its products and is involved in patent oppositions and litigation concerning its anti-PD-1 antibody, Keytruda. While the company believes it has strong defenses, unfavorable outcomes could materially impact its financial position.

MRK 10-Q Quarterly Report Q3 FY2015 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. reported its financial results for the third quarter and the first nine months of 2015. For the three months ended September 30, 2015, the company reported net income attributable to Merck & Co., Inc. of $1.8 billion, or $0.64 per diluted share, compared to $895 million, or $0.31 per diluted share, in the same period of 2014. For the nine months ended September 30, 2015, net income attributable to Merck & Co., Inc. was $3.5 billion, or $1.22 per diluted share, down from $4.6 billion, or $1.57 per diluted share, in the prior year period. Sales for the third quarter of 2015 decreased by 5% to $10.1 billion, impacted by a 7% unfavorable foreign exchange rate. Acquisitions, including Cubist Pharmaceuticals, contributed positively, while divestitures and the termination of the AstraZeneca LP relationship negatively impacted sales. The company continued to manage its operational costs, with restructuring programs progressing as planned. Key strategic initiatives include the ongoing development and launch of Keytruda in oncology and advancements in the diabetes portfolio.

Financial Highlights

52 data points

Beta

Revenue

$10.07B

0.6% Gross Margin

Net Income

$1.83B

0.2% Net Margin

EPS (Diluted)

$0.64

Total Assets

$101.23B

Cash & Equivalents

$7.55B

Free Cash Flow

$3.31B

Financial Statements

Beta

Revenue	$10.07B
Cost of Revenue	$3.76B
Gross Profit	$6.31B
R&D Expenses	$1.50B
SG&A Expenses	$2.47B
Interest Expense	$165.00M
Net Income	$1.83B
EPS (Basic)	$0.65
EPS (Diluted)	$0.64
Shares Outstanding (Basic)	2.81B
Shares Outstanding (Diluted)	2.84B

Key Highlights

1Net income attributable to Merck & Co., Inc. for Q3 2015 was $1.8 billion, a significant increase from $895 million in Q3 2014, driven by lower costs and gains from divestitures/acquisitions.
2Worldwide sales for Q3 2015 decreased by 5% year-over-year to $10.1 billion, primarily due to unfavorable foreign exchange rates (-7%) and the impact of divestitures.
3The acquisition of Cubist Pharmaceuticals in January 2015 contributed $362 million in revenue for Q3 2015, partially offsetting sales declines in other areas.
4Keytruda, an oncology drug, showed strong sales growth, reaching $159 million in Q3 2015 and $352 million year-to-date, highlighting its importance as a growth driver.
5Restructuring costs remained significant, with $113 million recognized in Q3 2015 related to ongoing programs aimed at improving efficiency.
6The company declared and paid dividends of $0.45 per share in Q3 2015, reflecting a commitment to returning capital to shareholders.
7Significant litigation and legal proceedings, particularly related to Vioxx and Fosamax, continue to be disclosed, with ongoing assessments of potential liabilities.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions